LIANHE TECHNOLOGY(002250)2024-05-22 13:07Financial Performance - In 2023, the company achieved an operating revenue of 644,215.28 thousand yuan, a decrease of 18.10% compared to the previous year [1] - The industrial business revenue was 641,015.50 thousand yuan, down 18.41% year-on-year [1] - The total profit was -40,205.38 thousand yuan, a decline of 142.57% compared to the previous year [1] - The net profit attributable to shareholders was -46,524.39 thousand yuan, a decrease of 166.76% year-on-year [1] - In Q1 2024, the company reported an operating revenue of 146,559.74 thousand yuan, down 25.12% year-on-year [1] - The net profit attributable to shareholders in Q1 2024 was 269.16 thousand yuan, a decrease of 93.96% compared to the same period last year [1] Asset Management and Strategy - The company is actively working to optimize asset utilization due to increased asset size and management challenges [2] - Strategies include rapid switching of production lines in multi-functional workshops and the "going out" strategy focusing on the UK and Malaysia [2] - The company aims to enhance domestic base development through external orders while maintaining high-quality sustainable growth [2] Industry Trends - The company anticipates a slowdown in the "de-inventory" trend in the agricultural protection industry in the second half of the year [2] - The recovery of patented products is expected to outpace that of generic drugs, which will be reflected in next year's financial statements [2] International Operations - The UK subsidiary faced losses in 2023 due to internal loan interest and low capacity utilization from the "de-inventory" trend [2] - The company is reviewing the UK operations to improve management and will adjust product offerings to enhance local production efficiency [2] Competitive Landscape - The company is preparing for challenges post-patent expiration by developing new technologies and optimizing production processes [3] - It believes that China's comprehensive supply chain and waste management systems provide a competitive edge against Indian competitors [3] Pharmaceutical and New Energy Business - The pharmaceutical segment is expanding its client base and enhancing R&D capabilities, having passed FDA and PMDA audits in 2023 [3] - New energy products like lithium hexafluorophosphate and lithium bis(fluorosulfonyl)imide are in trial production, with a focus on optimizing processes to reduce costs [3]